CD9 antigen on acute non-lymphoid leukemia cells: preferential expression by promyelocytic (M3) subtype

Leuk Res. 1991;15(6):457-61. doi: 10.1016/0145-2126(91)90056-y.

Abstract

A monoclonal antibody (S17-12), previously described to recognize subsets of myelomonocytic cells, is demonstrated to bind CD9 antigen, a surface marker of B-cell precursors, platelets and several non-hematopoietic tissues. The proportion of S17-12, CD9-positive leukemic cells was determined in 102 patients with acute non-lymphocytic leukemia. It was found to be above 75% in 14/22 M3 cases (including 3/3 of microgranular variant) and only in 1/80 cases of different FAB subtype. Complete reactivity (greater than 95%) of leukemic clonogenic cells with CD9 MoAB was restricted to 4/18 M3 cases. Therefore, a high proportion of CD9-positive cells seems to be peculiar to M3 cases. This may help in the diagnosis of cases that lack typical morphological features.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antigens, CD*
  • Antigens, Differentiation / metabolism
  • Antigens, Differentiation / physiology*
  • Binding, Competitive
  • Humans
  • Leukemia, Myeloid, Acute / immunology*
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Promyelocytic, Acute / immunology*
  • Leukemia, Promyelocytic, Acute / pathology
  • Membrane Glycoproteins*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Tetraspanin 29
  • Tumor Cells, Cultured

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation
  • CD9 protein, human
  • Membrane Glycoproteins
  • Tetraspanin 29